Adrenoleukodystrophy Pipeline Drugs and Companies Insight Report, 2024 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments by DelveInsight | Autobahn Therapeutics, Viking Therapeutics, SwanBio Th

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Adrenoleukodystrophy pipeline constitutes 10+ key companies continuously working towards developing 11+ Adrenoleukodystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Adrenoleukodystrophy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Adrenoleukodystrophy Market.

The Adrenoleukodystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Adrenoleukodystrophy Pipeline Report: https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Adrenoleukodystrophy treatment therapies with a considerable amount of success over the years.
• Adrenoleukodystrophy companies working in the treatment market are Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, Minoryx Therapeutics, and others, are developing therapies for the Adrenoleukodystrophy treatment
• Emerging Adrenoleukodystrophy therapies such as - ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others are expected to have a significant impact on the Adrenoleukodystrophy market in the coming years.
• In February 2024, The manufacturers of Nezglyal, Minoryx Therapeutics and Neuraxpharm Pharmaceuticals, plan to request a re-examination for conditional approval. This follows the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommendation to refuse marketing authorisation for Nezglyal (leriglitazone), an innovative orally bioavailable and selective peroxisome proliferator-activated receptor gamma agonist, developed for the treatment of cerebral adrenoleukodystrophy (cALD).

Adrenoleukodystrophy Overview
Adrenoleukodystrophy (ALD) is a rare genetic disorder that affects the adrenal glands, the nervous system, and the myelin sheath of nerve cells in the brain. It primarily affects males and is caused by mutations in the ABCD1 gene located on the X chromosome.

Get a Free Sample PDF Report to know more about Adrenoleukodystrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Adrenoleukodystrophy Drugs Under Different Phases of Clinical Development Include:
• ABX-002: Autobahn Therapeutics
• VK0214: Viking Therapeutics
• SBT101: SwanBio Therapeutics
• PXL065: Poxel SA
• PXL770: Poxel SA
• Leriglitazone : Minoryx Therapeutics
• OP101 : Orpheris
• Leriglitazone (MIN102): Minoryx Therapeutics

Route of Administration
Adrenoleukodystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal antibody
• Small molecule
• Peptide

Adrenoleukodystrophy Pipeline Therapeutics Assessment
• Adrenoleukodystrophy Assessment by Product Type
• Adrenoleukodystrophy By Stage and Product Type
• Adrenoleukodystrophy Assessment by Route of Administration
• Adrenoleukodystrophy By Stage and Route of Administration
• Adrenoleukodystrophy Assessment by Molecule Type
• Adrenoleukodystrophy by Stage and Molecule Type

DelveInsight's Adrenoleukodystrophy Report covers around 11+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Adrenoleukodystrophy product details are provided in the report. Download the Adrenoleukodystrophy pipeline report to learn more about the emerging Adrenoleukodystrophy therapies
https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Adrenoleukodystrophy Therapeutics Market include:
Key companies developing therapies for Adrenoleukodystrophy are - AstraZeneca, Cipla Inc., Abbott, Bayer AG, Merck KGaA, GlaxoSmithKline plc, agtc, bluebird bio, MINORYX THERAPEUTICS SL, SwanBio Therapeutics, Inc., Viking Therapeutics, Novartis AG, Sanofi, Pfizer Inc., Sumitomo Corporation, Johnson & Johnson Private Limited, and others.

Adrenoleukodystrophy Pipeline Analysis:
The Adrenoleukodystrophy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Adrenoleukodystrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenoleukodystrophy Treatment.
• Adrenoleukodystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Adrenoleukodystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenoleukodystrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Adrenoleukodystrophy drugs and therapies
https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Adrenoleukodystrophy Pipeline Market Drivers
• Increasing awareness towards genetic diseases coupled with genetic counseling, rise in the number of R&D activities are some of the important factors that are fueling the Adrenoleukodystrophy Market.

Adrenoleukodystrophy Pipeline Market Barriers
• However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the Adrenoleukodystrophy Market growth.

Scope of Adrenoleukodystrophy Pipeline Drug Insight
• Coverage: Global
• Key Adrenoleukodystrophy Companies: Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, Minoryx Therapeutics, and others
• Key Adrenoleukodystrophy Therapies: ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others
• Adrenoleukodystrophy Therapeutic Assessment: Adrenoleukodystrophy current marketed and Adrenoleukodystrophy emerging therapies
• Adrenoleukodystrophy Market Dynamics: Adrenoleukodystrophy market drivers and Adrenoleukodystrophy market barriers

Request for Sample PDF Report for Adrenoleukodystrophy Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Adrenoleukodystrophy Report Introduction
2 Adrenoleukodystrophy Executive Summary
3 Adrenoleukodystrophy Overview
4 Adrenoleukodystrophy- Analytical Perspective In-depth Commercial Assessment
5 Adrenoleukodystrophy Pipeline Therapeutics
6 Adrenoleukodystrophy Late Stage Products (Phase II/III)
7 Adrenoleukodystrophy Mid Stage Products (Phase II)
8 Adrenoleukodystrophy Early Stage Products (Phase I)
9 Adrenoleukodystrophy Preclinical Stage Products
10 Adrenoleukodystrophy Therapeutics Assessment
11 Adrenoleukodystrophy Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Adrenoleukodystrophy Key Companies
14 Adrenoleukodystrophy Key Products
15 Adrenoleukodystrophy Unmet Needs
16 Adrenoleukodystrophy Market Drivers and Barriers
17 Adrenoleukodystrophy Future Perspectives and Conclusion
18 Adrenoleukodystrophy Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:

Adrenoleukodystrophy Epidemiology https://www.delveinsight.com/report-store/adrenoleukodystrophy-epidemiology?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Adrenoleukodystrophy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Glioblastoma Market
https://www.delveinsight.com/report-store/glioblastoma-market
DelveInsight's "Glioblastoma Market Insights, Epidemiology and Market Forecast- 2032" report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Sickle Cell Disease Market
https://www.delveinsight.com/report-store/sickle-cell-disease-6mm-market
DelveInsight's "Sickle Cell Disease Market Insights, Epidemiology and Market Forecast- 2032" report delivers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Among the 6MM countries the Sickle cell disease market size was valued ~USD 650 million in 2023 and is expected to increase throughout the forecast period (2024-2034).

Holter Monitor Market
https://www.delveinsight.com/report-store/holter-monitor-market
The Global Holter Monitor market will grow at a CAGR of 6.13% during the forecast period from 2024 to 2030. The stellar growth observed in the market is primarily due to the growing burden of various cardiovascular disorders which leads to abnormal heart rhythm such as atrial fibrillation, and heart palpitations, among others that may require monitoring through Holter monitors.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.